Leerink Partnrs Has Bearish Estimate for ARWR Q3 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Leerink Partnrs reduced their Q3 2025 earnings per share (EPS) estimates for shares of Arrowhead Pharmaceuticals in a research note issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings of ($0.52) per share for the quarter, down from their previous estimate of ($0.51). The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.40) per share. Leerink Partnrs also issued estimates for Arrowhead Pharmaceuticals’ Q4 2025 earnings at ($0.48) EPS and FY2025 earnings at ($2.06) EPS.

A number of other equities analysts have also recently issued reports on ARWR. Citigroup reduced their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 27th. Chardan Capital restated a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Thursday, December 12th. Sanford C. Bernstein decreased their price objective on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research note on Friday, November 29th. Piper Sandler cut their target price on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. Finally, StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $43.33.

Arrowhead Pharmaceuticals Stock Down 3.6 %

Shares of NASDAQ ARWR opened at $20.76 on Friday. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 2.06. The firm has a market capitalization of $2.58 billion, a PE ratio of -4.14 and a beta of 0.97. The firm’s 50-day moving average is $20.73 and its 200-day moving average is $22.04. Arrowhead Pharmaceuticals has a 1 year low of $17.05 and a 1 year high of $36.72.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. R Squared Ltd bought a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth $38,000. Values First Advisors Inc. acquired a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth about $52,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Arrowhead Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after buying an additional 788 shares during the last quarter. KBC Group NV grew its holdings in shares of Arrowhead Pharmaceuticals by 45.9% in the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 1,644 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at about $149,000. 62.61% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CFO Kenneth Allen Myszkowski sold 27,167 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $19.83, for a total value of $538,721.61. Following the completion of the transaction, the chief financial officer now directly owns 473,433 shares of the company’s stock, valued at approximately $9,388,176.39. This represents a 5.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider James C. Hamilton sold 32,729 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $19.82, for a total value of $648,688.78. Following the completion of the sale, the insider now directly owns 272,122 shares in the company, valued at $5,393,458.04. This represents a 10.74 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 146,473 shares of company stock valued at $2,937,847. 4.50% of the stock is owned by corporate insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.